Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II study examines IMC-C225 in combination with other agents for NSCLC

Feb. 8, 2001

NewBiotics and Elan form joint venture to develop colon cancer therapy

Feb. 8, 2001

Japanese labs design new series of ribonucleotide reductase inhibitors

Feb. 7, 2001

YM BioSciences extends EGF cancer vaccine trial to include U.K. sites

Feb. 7, 2001

Results with INGN-201 indicate new strategy for cancer immunotherapy

Feb. 7, 2001

Promising preliminary clinical results reported for Cell Therapeutics' PG-TXL

Feb. 7, 2001

Phase III trials of Thymitaq to begin in Canada

Feb. 7, 2001

Phase I leukemia data on Troxatyl published

Feb. 6, 2001

Polyketide macrolides produced by mycobacteria exert anticancer, antiinflammatory effects

Feb. 5, 2001

IMC-C225 granted fast track designation for refractory colorectal carcinoma

Feb. 5, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...